The PTPN11 Knockout U2OS Cell Line is a CRISPR/Cas9-edited knockout cell line generated from the U2OS human osteosarcoma line through targeted disruption of the PTPN11 gene. This model provides a stable loss-of-function system for studying the role of SHP-2 phosphatase in oncogenic signaling and disease pathology. The use of CRISPR/Cas9 technology ensures specific gene inactivation, enabling researchers to dissect PTPN11-dependent mechanisms in a well-characterized cellular background.
The U2OS cell line was originally established from a moderately differentiated sarcoma of the tibia of a 15-year-old female patient. It is a widely utilized model in bone cancer research, characterized by adherent growth and an epithelial-like morphology. U2OS cells retain key signaling pathways relevant to osteosarcoma biology and are commonly employed for studies of cell proliferation, apoptosis, and metastasis. The PTPN11 knockout derivative is cultivated under standard conditions and maintains the essential phenotypic traits of the parental line, facilitating comparative analyses between wild-type and gene-disrupted states.
PTPN11 encodes the non-receptor protein tyrosine phosphatase SHP-2, which functions as a critical positive regulator of the RAS-MAPK pathway. Upon stimulation of upstream receptors such as EGFR, PDGFR, and FGFR, SHP-2 is recruited to phosphorylated tyrosine motifs on adaptor proteins including Gab1, Gab2, and FRS2. SHP-2 dephosphorylates inhibitory phosphotyrosines on these adaptors and on the negative regulator Sprouty, thereby relieving suppression and promoting the activation of the RAS-GTPase cycle. Through its interaction with Grb2 and Sos1, SHP-2 facilitates signal transmission to the RAF-MEK-ERK kinase cascade. In parallel, SHP-2 contributes to PI3K-AKT signaling, influencing cell survival and metabolism. Additional downstream effectors such as paxillin, STAT5A, and FAK are modulated by SHP-2 activity, linking the phosphatase to integrin-mediated adhesion and cytoskeletal dynamics.
In U2OS osteosarcoma cells, SHP-2 is implicated in the regulation of proliferative and pro-migratory signals downstream of multiple receptor tyrosine kinases. Loss of PTPN11 disrupts this signaling hub, potentially attenuating MAPK and AKT pathway outputs and altering cellular responses to growth factors and cytokines. This knockout cell line therefore offers a valuable platform for investigating how SHP-2 coordinates oncogenic pathway crosstalk in a bone cancer setting. It enables the study of SHP-2-dependent transcriptional programs, cell cycle progression, and anchorage-independent growth, all of which are relevant to osteosarcoma pathogenesis and therapeutic intervention.
This cell line supports a broad range of applications, including mechanistic studies of RAS-MAPK and JAK-STAT signaling, preclinical modeling of Noonan syndrome and juvenile myelomonocytic leukemia, and drug target validation for SHP-2 inhibitors. Representative assays include western blotting for phospho-ERK and total SHP-2, RT-qPCR for PTPN11 transcript levels, immunofluorescence localization, and phospho-signaling analysis. Functional readouts such as cell proliferation, colony formation, and migration/invasion assays can be performed to assess the impact of PTPN11 loss. The model is also suitable for co-culture experiments and high-throughput screening of small-molecule modulators. For further information or technical inquiries, please contact Ascent Research.
